Expression of serotonin receptors 2B and 4 in human prostate cancer tissue and effects of their antagonists on prostate cancer cell lines

被引:66
作者
Dizeyi, N [1 ]
Bjartell, A
Hedlund, P
Taskén, KA
Gadaleanu, V
Abrahamsson, PA
机构
[1] Lund Univ, Malmo Univ Hosp, Dept Urol, SE-20502 Malmo, Sweden
[2] Lund Univ, Malmo Univ Hosp, Dept Clin Pharmacol, SE-20502 Malmo, Sweden
[3] Lund Univ, Malmo Univ Hosp, Dept Pathol, SE-20502 Malmo, Sweden
[4] Univ Oslo, Fac Div Aker Univ Hosp, Oslo Urol Univ Clin, Oslo, Norway
关键词
immunohistochemistry; RT-PCR; BrdU assay; androgen-independent tumour cells;
D O I
10.1016/j.eururo.2005.02.006
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives: Overexpression of receptors to neuroendocrine (NE) cell products has been suggested to contribute to development of hormone-refractory prostate cancer (HRPC). In this study, we evaluated the expression of 5-HTR2B and 5-HTR4 in HRPC, and the effects of their antagonist on PC cell line growth. Methods: Proteins and mRNA expression was determined by immunohistochemistry, western blot and RT-PCR. Growth inhibition of PC cell lines was determined in vitro using ELISA-BrdU proliferation assay and cell cycle was evaluated by flow cytometry. Results: Immunostaining of 5-HTR2B was observed in low-grade and high-grade tumours, PIN and BPH cells, and in vascular endothelial cells, whereas 5-HTR4 was found predominantly in high-grade tumours. This result was confirmed by western blot analysis. At the mRNA level, 5-HTR4 mRNA was expressed in DU145 and LNCaP cells. Antagonists to both receptor subtypes inhibited proliferation of PC cells in a dose-dependent manner. Conclusions: The present result indicate that 5-HTRs are present at various tumour stages and that antagonists to these receptors can inhibit the proliferative activity of androgen-independent PC cell lines. (c) 2005 Elsevier B.V All rights reserved.
引用
收藏
页码:895 / 900
页数:6
相关论文
共 23 条
  • [1] ABDUL M, 1994, ANTICANCER RES, V14, P1215
  • [2] PEPTIDE-HORMONEACTIVE AND SEROTONIN-IMMUNOREACTIVE TUMOR-CELLS IN CARCINOMA OF THE PROSTATE
    ABRAHAMSSON, PA
    WADSTROM, LB
    ALUMETS, J
    FALKMER, S
    GRIMELIUS, L
    [J]. PATHOLOGY RESEARCH AND PRACTICE, 1987, 182 (03) : 298 - 307
  • [3] Histological, immunohistochemical, ultrastructural and biochemical study of human gastric composite tumor: Expression of the serotonin-2B receptor by the neuroendocrine component
    Brouland, JP
    Manivet, P
    Brocheriou-Spelle, I
    Wassef, M
    Le Bodic, MF
    Lavergne, A
    Launay, JM
    [J]. ENDOCRINE PATHOLOGY, 2001, 12 (01) : 77 - 86
  • [4] Effects of serotonin and vasopressin on cortisol production from an adrenocortical tumor causing subclinical Cushing's syndrome
    Contesse, V
    Reznik, Y
    Duparc, C
    Perraudin, V
    Vaudry, H
    Kuhn, JM
    Lefebvre, H
    [J]. ENDOCRINE RESEARCH, 2002, 28 (04) : 787 - 791
  • [5] DISANTAGNESE PA, 1992, CANCER-AM CANCER SOC, V70, P254, DOI 10.1002/1097-0142(19920701)70:1+<254::AID-CNCR2820701312>3.0.CO
  • [6] 2-E
  • [7] Expression of serotonin receptors and role of serotonin in human prostate cancer tissue and cell lines
    Dizeyi, N
    Bjartell, A
    Nilsson, E
    Hansson, J
    Gadaleanu, V
    Cross, N
    Abrahamsson, PA
    [J]. PROSTATE, 2004, 59 (03) : 328 - 336
  • [8] Autocrine and paracrine signaling through neuropeptide receptors in human cancer
    Heasley, LE
    [J]. ONCOGENE, 2001, 20 (13) : 1563 - 1569
  • [9] Molecular, pharmacological and functional diversity of 5-HT receptors
    Hoyer, D
    Hannon, JP
    Martin, GR
    [J]. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2002, 71 (04) : 533 - 554
  • [10] HOYER D, 1994, PHARMACOL REV, V46, P157